Pfizer Joins Molecular Glue Degradation Race Via Pact With Triana

Deal Snapshot: Pfizer is hoping Triana’s approach to molecular glue degradation can yield novel approaches to difficult targets in multiple therapeutic areas, including cancers.

(Shutterstock)

More from Deals

More from Scrip